Evidence map›Paper›PMID 39512652›Full record

ArticleJournal of the Royal Statistical Society. Series A, (Statistics in Society)2020

Brand

Lamar Hunt, Irene B Murimi, Jodi B Segal, Marissa J Seamans, Daniel O Scharfstein, Ravi Varadhan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Royal Statistical Society. Series A, (Statistics in Society), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lamar HuntJohns Hopkins University Bloomberg School of Public Health, Baltimore, USA.
Irene B MurimiMassachusetts College of Pharmacy and Health Sciences, Boston, USA.
Jodi B SegalJohns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Marissa J SeamansJohns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Daniel O ScharfsteinJohns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Ravi VaradhanJohns Hopkins School of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.

Funding

NIDA Epidemiology Training Program: Johns Hopkins UniversityT32DA007292 · NIDA · JOHNS HOPKINS UNIVERSITY · PI RENEE M. JOHNSON, Brion S Maher · 1993 to 2026
$17.7M
NHLBI Training Program in PharmacoepidemiologyT32HL139426 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI G. Caleb Alexander, JODI B. SEGAL · 2018 to 2026
$2.5M
FDA HHS U01 FD005556NHLBI NIH HHS T32 HL139426NIDA NIH HHS T32 DA007292
6 · The paper itself

Abstract

Whereas generic drugs offer a cost-effective alternative to brand name drugs, regulators need a method to assess therapeutic equivalence in a post-market setting. We develop such a method in the context of assessing the therapeutic equivalence of immediate release venlafaxine, based on a large insurance claims data set provided by OptumLabs

Indexed as

G-computationGeneric drugsRegression discontinuityTemporal confoundingTherapeutic equivalenceTime-varying confoundingVenlafaxine

Identifiers

PMID39512652
PMCPMC11542766

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.